# US 2013/0158105 A1 · Conformation-selective nucleic acid inhibitors of ampa glutamate receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158105 A1
- Document ID: US20130158105A1
- Status: Published application
- Kind: A1
- Application number: 13/775,947
- Filed: 2013-02-25
- Published: 2013-06-20
- Earliest claimed: 2010-10-08
- Assignees: The Research Foundation for The State University of New York
- Inventors: Li NIU; Zhen HUANG
- Web page: https://patentgrep.com/patent/US20130158105A1

## CPC

- C07H 21/02: with ribosyl as saccharide radical
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/04: with deoxyribosyl as saccharide radical
- G01N 2333/70571: for neuromediators, e.g. serotonin receptor, dopamine receptor
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to novel nucleic acid ligands or aptamers that demonstrate potent and selective inhibition of the open-channel conformation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors.

## Claims

### Claim 1

A synthetic nucleic acid that binds to an open-channel conformation of a glutamate ion channel receptor, said nucleic acid comprising the nucleotide sequence of SEQ ID NO: 7.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The synthetic nucleic acid of claim 1, wherein the nucleic acid is RNA.

### Claim 4 (depends on 1)

The synthetic nucleic acid of claim 1, wherein the nucleic acid contains between 45 and 120 nucleotides.

### Claim 5 (depends on 1)

The synthetic nucleic acid of claim 1, wherein the nucleic acid contains between 50 and 110 nucleotides.

### Claim 6 (depends on 1)

The synthetic nucleic acid of claim 1, wherein the nucleic acid contains between 56 and 100 nucleotides.

### Claim 7 (depends on 1)

The synthetic nucleic acid of claim 1, wherein said nucleic acid contains one or more chemically modified nucleotides.

### Claim 8 (depends on 1)

The synthetic nucleic acid of claim 1 wherein the one or more chemically modified nucleotides has a 2′ fluoro substituent.

### Claim 9 (depends on 1)

The synthetic nucleic acid of claim 1, wherein said nucleic acid inhibits glutamate receptor function.

### Claim 10 (depends on 1)

The synthetic nucleic acid of claim 1, wherein said nucleic acid has a KI<1 μM.

### Claim at position 11

11-12. (canceled)

### Claim 13 (depends on 1)

The isolated nucleic acid of claim 1 wherein the glutamate receptor is of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subtype.

### Claim at position 13

14-20. (canceled)

### Claim 21 (depends on 1)

A method of inhibiting the function of a glutamate receptor comprising contacting said receptor with the aptamer of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the glutamate receptor is of the AMPA subtype.

### Claim 23

An isolated DNA that codes for an RNA wherein the RNA comprises the nucleotide sequence of SEQ ID NO: 7.

### Claim 24 (depends on 1)

A method of inhibiting a glutamate receptor comprising contacting said receptor with the nucleic acid of claim 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the glutamate receptor is of the AMPA subtype.

### Claim 26 (depends on 1)

A pharmaceutical composition comprising a nucleic acid according to claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 20

27-28. (canceled)
